Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

Camille TlemsaniParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

, MD,

Olivier HuillardParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Jennifer ArrondeauParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Pascaline Boudou-RouquetteParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Anatole CessotParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Benoit BlanchetParis Descartes University, Cochin Hospital, AP-HP, Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Audrey Thomas-SchoemannParis Descartes University, Cochin Hospital, AP-HP, Pharmacokinetics and Pharmacochemistry Unit, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France;Paris Descartes University, Paris Pharmaceutical Research Center, UMR 8638 CNRS, Faculty of Pharmacy, Paris, France

Romain CoriatParis Descartes University, Cochin Hospital, AP-HP, Gastroenterology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France

Jean-Philippe DurandParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Julie GirouxParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

Jérôme AlexandreParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

François GoldwasserParis Descartes University, Cochin Hospital, AP-HP, Medical Oncology Department, Angiogenesis Inhibitors Multidisciplinary Study Group (CERIA), Paris, France33 1 58 41 17 46; 33 1 58 41 17 45; [email protected]

show all

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

Articles from other publishers (23)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

Citations (27)

Read on this site (4)

Articles from other publishers (23)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date